Paharik, Alexandra E.
Schreiber, Henry L. IV
Spaulding, Caitlin N.
Dodson, Karen W.
Hultgren, Scott J.
Funding for this research was provided by:
National Institutes of Health (RO1DK051406, R01AI048689, P50DK064540, 1F31DK107057)
Article History
First Online: 14 December 2017
Competing interests
: SJH is an inventor on US patent US8937167 B2, which covers the use of mannoside-based FimH ligand antagonists for the treatment of disease. SJH has ownership interest in Fimbrion Therapeutics, and may benefit if the company is successful in marketing mannosides.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.